Quantisnow Logo
Dashboard

Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$MNMD
Medicinal Chemicals and Botanical Products
Health Care
Get the next $MNMD alert in real time by email
8-K
false000181381400018138142024-12-162024-12-16

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 16, 2024

 

 

Mind Medicine (MindMed) Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

British Columbia

001-40360

98-1582438

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

One World Trade Center

Suite 8500

 

New York, New York

 

10007

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (212) 220-6633

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Shares

 

MNMD

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 8.01 Other Events.

On December 16, 2024, Mind Medicine (MindMed) Inc. (“the Company”) issued a press release announcing the first patient dosed in the Company's Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.

Description

99.1

 

Press Release, dated December 16, 2024

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

Date:

December 16, 2024

By:

/s/ Robert Barrow

 

 

 

Robert Barrow
Chief Executive Officer

 

Get the next $MNMD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MNMD

DatePrice TargetRatingAnalyst
1/28/2025$23.00Outperform
Evercore ISI
12/20/2024$20.00Buy
Chardan Capital Markets
10/14/2024$20.00Outperform
Leerink Partners
7/24/2024$36.00Buy
ROTH MKM
5/29/2024$27.00Outperform
Robert W. Baird
4/15/2024$20.00Outperform
Leerink Partners
12/5/2023$9.00Buy
Canaccord Genuity
12/9/2022$25.00Buy
ROTH Capital
More analyst ratings

$MNMD
 Press Releases

Fastest customizable press release news feed in the world

See more

  • MindMed Announces New Employee Inducement Grants

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 88,950 common shares of the Company (the "Options"), with an effective grant date of March 24, 2025. The Options have an exercise price equal to the closing price of MindMed's common shares on March 21, 2025, the last trading day on which MindMed's common shares traded prior to the date of the grant, and will vest over a four-year period with 25% vesting on the f

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

  • MindMed Appoints Matt Wiley as Chief Commercial Officer

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer (CCO). In his new role, Mr. Wiley will serve as a member of the executive team, overseeing the Company's commercial vision and strategy as it prepares for the potential launch of its first product, MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

  • MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

    --First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama-- --On track to initiate Emerge, the first Phase 3 study of MM120 ODT in Major Depressive Disorder (MDD) in 1H of 2025-- --Raised approximately $250 million in gross proceeds through two equity financings in 2024; cash and cash equivalents of $273.7 million as of December 31, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 8:00

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

$MNMD
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MNMD
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$MNMD
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MNMD
 SEC Filings

See more

$MNMD
 Leadership Updates

Live Leadership Updates

See more

  • MindMed Appoints Matt Wiley as Chief Commercial Officer

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer (CCO). In his new role, Mr. Wiley will serve as a member of the executive team, overseeing the Company's commercial vision and strategy as it prepares for the potential launch of its first product, MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

  • MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive innovation and growth of MindMed's R&D operations as the Company prepares to initiate three Phase 3 studies of MM120 orally disintegrating tablet (ODT) in generalized anxiety disorder and major depressive disorder. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203094211/en/Javier Muniz,

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

  • MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee the Company's regulatory and quality functions, as well as its product registration strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241118653031/en/(Photo: Business Wire) "We are thrilled to welcome Gregg to the MindMed team. His leadership will strengthen o

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

$MNMD
 Financials

Live finance-specific insights

See more

  • MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

    --First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama-- --On track to initiate Emerge, the first Phase 3 study of MM120 ODT in Major Depressive Disorder (MDD) in 1H of 2025-- --Raised approximately $250 million in gross proceeds through two equity financings in 2024; cash and cash equivalents of $273.7 million as of December 31, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 8:00

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

  • MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, March 6, 2025 to report financial results for the fourth quarter and year ended December 31, 2024, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

  • MindMed Reports Third Quarter 2024 Financial Results and Business Updates

    --On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated in the first half of 2026-- --On track to initiate the Phase 3 Panorama study of MM120 ODT in GAD and the Phase 3 Emerge study of MM120 ODT in Major Depressive Disorder (MDD) in the first half of 2025-- --Cash and cash equivalents of $295.3 million as of September 30, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 4:30 p.m. EST-- Mind Medicine (MindMed) Inc.

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

$MNMD
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more